Bafna Pharmaceuticals Limited (NSE:BAFNAPH)
India
· Delayed Price · Currency is INR 72.00
-3.34 (-4.43%)
May 9, 2025, 1:39 PM IST
Bafna Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2015 - 2019 |
| Operating Revenue | 1,482 | 1,525 | 1,153 | 851.4 | 712.18 | 424.73 | Upgrade
|
| Revenue | 1,482 | 1,525 | 1,153 | 851.4 | 712.18 | 424.73 | Upgrade
|
| Revenue Growth (YoY) | -3.34% | 32.18% | 35.48% | 19.55% | 67.68% | -2.67% | Upgrade
|
| Cost of Revenue | 1,051 | 1,073 | 770.12 | 515.41 | 455.05 | 275.02 | Upgrade
|
| Gross Profit | 431.35 | 452.15 | 383.38 | 336 | 257.13 | 149.71 | Upgrade
|
| Selling, General & Admin | 216.35 | 198.38 | 166.34 | 149.37 | 122.47 | 105.63 | Upgrade
|
| Other Operating Expenses | 101.26 | 138.44 | 42.94 | 65.29 | 28.43 | 31.16 | Upgrade
|
| Operating Expenses | 377.81 | 387.52 | 265.66 | 269.59 | 195.68 | 169.45 | Upgrade
|
| Operating Income | 53.54 | 64.63 | 117.72 | 66.41 | 61.46 | -19.75 | Upgrade
|
| Interest Expense | -22.32 | -19.38 | -17.98 | -5.24 | -0.89 | -0.01 | Upgrade
|
| Interest & Investment Income | 1.25 | 1.25 | 0.45 | 0.34 | 0.4 | 0.39 | Upgrade
|
| Currency Exchange Gain (Loss) | 16.72 | 16.72 | 14.77 | 3.61 | 3.84 | 1.53 | Upgrade
|
| Other Non Operating Income (Expenses) | -3.3 | 9.6 | -2.3 | 8.5 | -6.54 | -0.95 | Upgrade
|
| EBT Excluding Unusual Items | 45.89 | 72.82 | 112.67 | 73.62 | 58.27 | -18.78 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.66 | 0.66 | 1.96 | - | - | - | Upgrade
|
| Other Unusual Items | -3.57 | - | - | -21.57 | - | - | Upgrade
|
| Pretax Income | 42.97 | 73.48 | 116.16 | 52.16 | 58.27 | -18.78 | Upgrade
|
| Income Tax Expense | - | - | 2.78 | - | - | - | Upgrade
|
| Earnings From Continuing Operations | 42.97 | 73.48 | 113.38 | 52.16 | 58.27 | -18.78 | Upgrade
|
| Net Income to Company | 42.97 | 73.48 | 113.38 | 52.16 | 58.27 | -252.04 | Upgrade
|
| Net Income | 42.97 | 73.48 | 113.38 | 52.16 | 58.27 | -252.04 | Upgrade
|
| Net Income to Common | 42.97 | 73.48 | 113.38 | 52.16 | 58.27 | -252.04 | Upgrade
|
| Net Income Growth | -61.85% | -35.19% | 117.36% | -10.48% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 24 | 24 | 24 | 24 | 24 | 2 | Upgrade
|
| Shares Outstanding (Diluted) | 24 | 24 | 24 | 24 | 24 | 2 | Upgrade
|
| Shares Change (YoY) | 0.39% | - | - | -0.13% | 901.24% | 47.48% | Upgrade
|
| EPS (Basic) | 1.82 | 3.11 | 4.79 | 2.21 | 2.46 | -106.54 | Upgrade
|
| EPS (Diluted) | 1.82 | 3.11 | 4.79 | 2.21 | 2.46 | -106.54 | Upgrade
|
| EPS Growth | -62.00% | -35.15% | 117.23% | -10.36% | - | - | Upgrade
|
| Free Cash Flow | - | -60.93 | -17.66 | 21.87 | -197.04 | -356.97 | Upgrade
|
| Free Cash Flow Per Share | - | -2.58 | -0.75 | 0.93 | -8.32 | -150.90 | Upgrade
|
| Gross Margin | 29.11% | 29.66% | 33.24% | 39.46% | 36.10% | 35.25% | Upgrade
|
| Operating Margin | 3.61% | 4.24% | 10.21% | 7.80% | 8.63% | -4.65% | Upgrade
|
| Profit Margin | 2.90% | 4.82% | 9.83% | 6.13% | 8.18% | -59.34% | Upgrade
|
| Free Cash Flow Margin | - | -4.00% | -1.53% | 2.57% | -27.67% | -84.05% | Upgrade
|
| EBITDA | 100.95 | 114.58 | 171.07 | 121.34 | 106.24 | 12.92 | Upgrade
|
| EBITDA Margin | 6.81% | 7.51% | 14.83% | 14.25% | 14.92% | 3.04% | Upgrade
|
| D&A For EBITDA | 47.41 | 49.95 | 53.34 | 54.93 | 44.78 | 32.67 | Upgrade
|
| EBIT | 53.54 | 64.63 | 117.72 | 66.41 | 61.46 | -19.75 | Upgrade
|
| EBIT Margin | 3.61% | 4.24% | 10.21% | 7.80% | 8.63% | -4.65% | Upgrade
|
| Effective Tax Rate | - | - | 2.40% | - | - | - | Upgrade
|
| Revenue as Reported | 1,504 | 1,560 | 1,186 | 868.38 | 719.67 | 427.28 | Upgrade
|
| Advertising Expenses | - | 4.72 | 3.66 | 0.96 | 0.56 | 0.62 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.